HSG
ABUS icon

Helen Stephens Group’s Arbutus Biopharma ABUS Stock Holding History

Helen Stephens Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,000
Closed -$50K – 87
2024
Q3 		$50K Buy
+13,000
New +$49.9K 0.02% 89

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Helen Stephens Group's ABUS Position: Q4 2024 in Review

Helen Stephens Group sold out of Arbutus Biopharma (ABUS) in Q4 2024, closing a stake of 13,000 shares — an estimated $50K sold.

Helen Stephens Group first reported a position in ABUS in Q3 2024 and held it in 1 quarter. The position peaked at $50K in Q3 2024. 153 funds tracked by Wall St. Rank hold ABUS as of Q4 2024.

  • Helen Stephens Group reported no remaining Arbutus Biopharma position as of Q4 2024 after selling out during the quarter.
  • Helen Stephens Group sold 13,000 Arbutus Biopharma shares in Q4 2024, an estimated $50K.
  • Helen Stephens Group first reported a position in Arbutus Biopharma in Q3 2024 and held it in 1 quarter.
  • Helen Stephens Group's Arbutus Biopharma position peaked at $50K in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2024.

Based on Helen Stephens Group's 13F filing for Q4 2024, filed 15 Jan 2025.